TD Asset Management
FBIO icon

TD Asset Management’s Fortress Biotech FBIO Stock Holding History

TD Asset Management’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-2,953
Closed -$311K – 1299
2013
Q3 		$311K Buy
2,953
+220
+8% +$27K ﹤0.01% 1099
2013
Q2 		$353K Buy
+2,733
New +$403K ﹤0.01% 1000

Other funds holding FBIO

EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
MOACM
Mutual of America Capital Management New York $8.8B AUM 29.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return

TD Asset Management's FBIO Position: Q4 2013 in Review

TD Asset Management sold out of Fortress Biotech (FBIO) in Q4 2013, closing a stake of 2,953 shares — an estimated $311K sold.

TD Asset Management first reported a position in FBIO in Q2 2013 and held it in 2 quarters. The position peaked at $353K in Q2 2013. 60 funds tracked by Wall St. Rank hold FBIO as of Q4 2013.

  • TD Asset Management reported no remaining Fortress Biotech position as of Q4 2013 after selling out during the quarter.
  • TD Asset Management sold 2,953 Fortress Biotech shares in Q4 2013, an estimated $311K.
  • TD Asset Management first reported a position in Fortress Biotech in Q2 2013 and held it in 2 quarters.
  • TD Asset Management's Fortress Biotech position peaked at $353K in Q2 2013.
  • 60 funds tracked by Wall St. Rank held Fortress Biotech as of Q4 2013.

Based on TD Asset Management's 13F filing for Q4 2013, filed 7 Feb 2014.